Agenda: Day 1  | Day 2  |

 US Healthcare Reform-A New Dawn?

With the US market accounting for half of global drug sales, any changes as a result of current US healthcare reforms will have a significant impact on the global pharmaceutical industry. Extensions in insurance coverage to an additional 31m Americans can be expected to increase the overall size of the market, but could equally be counteracted by the prospect of increasing government intervention in pricing and reimbursement decisions.  

·          How should life science companies view the US market in the light of current reforms?

·          What can we expect from the FDA in the new era?

·          What role will comparative effectiveness play in the US market?

·          What will be the impact, if any, of the reforms on innovation in the US and internationally? 

 As countries around the globe tackle the growing burden of costs and reform their healthcare systems, they are doing so around concepts of comparative effectiveness and value-based pricing-with major implications for life science companies and their global sales revenues.Yet the yardsticks by which these bodies are measuring value and outcomes varies from market to market, adding yet another layer of complexity for pharma companies with product sales in multiple markets.

·          To what extent is evidence based medicine /comparative effectiveness becoming a global phenomenon?

·          What are the different approaches being applied to evaluate and measure economic outcomes of different drugs in the different markets?

·          Towards a universal definition of value? To what degree are systems converging? Are existing and proposed models for determining cost and efficiency sufficiently robust? 

A Future Focussed on Value and Outcomes-Transforming the Business of Pharma 

The new international focus on value and outcomes as the basis of pricing and reimbursement decisions for pharmaceutical products and devices will have far reaching consequences for the industry. It will influence which drugs make their way through the labs. It will require a new type of sale force focussed on selling outcomes rather than products, and it will require an understanding that access and ownership of data will become the new competitive edge for the business. 

·          Faced with the realities of this new order, how can life science companies prepare?

·          As comparative effectiveness and retrospective analysis of outcomes becomes the norm, what can the industry do to ensure that decisions on outcomes are fair and informed?

·          As consumers, likewise, become purveyors of value in the industry, how can life sciences companies build an understanding of, and influence their prescription choices? 

CFO Panel: Positioning for Growth

As CFOs move from keeping the score to "shaping the play", the initiatives they undertake, and the guidance they provide to strategy are having an increasingly important role in driving future revenue and the sustainable growth of the company. So what are the issues keeping the CFOs of today's life science companies awake at night, and what do they see as the trends shaping the business? 

·          Maximising shareholder returns from M&A

·          Understanding and planning for the tax implications of the emerging new business models of pharma e.g. outcome inspired end-to-end service offerings, new external and global collaborations.

·          Financing R&D-perspectives of CFO's and financiers on the new emerging R&D business models to finance early stage research, prospects for biotech financing in a post crisis world 

Three Decades of Responding to AIDS: Lessons for Global Health and Chronic Diseases